- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Enveda Reports Positive Phase 1b Results for New Drug
Biotech firm's experimental treatment shows promise in clinical trial for patients with chronic condition
Mar. 31, 2026 at 1:24pm
Got story updates? Submit your updates here. ›
Enveda's new drug candidate ENV-294 shows promise in early clinical trials, offering hope for those living with a chronic condition.Boulder TodayEnveda, a Colorado-based biotech company, has announced positive results from a Phase 1b clinical trial of its experimental drug ENV-294 in patients with a chronic condition. The trial evaluated the safety and efficacy of the new treatment, with the findings suggesting it could be a promising option for those living with the disease.
Why it matters
The successful Phase 1b trial represents an important milestone for Enveda as it works to develop new therapies for underserved patient populations. If ENV-294 continues to show promise in further clinical testing, it could eventually provide a much-needed treatment option for those struggling with this chronic condition.
The details
The Phase 1b trial enrolled a small group of patients with the chronic condition and assessed the safety, tolerability, and preliminary efficacy of ENV-294. Enveda reported that the drug was well-tolerated, with no serious adverse events observed. Additionally, the data suggested potential therapeutic benefits, though further research is needed to confirm these initial findings.
- The Phase 1b clinical trial was conducted in March 2026.
The players
Enveda
A Colorado-based biotech company focused on developing new treatments for chronic conditions.
ENV-294
Enveda's experimental drug that was evaluated in the Phase 1b clinical trial.
What they’re saying
“We are encouraged by the positive results from this Phase 1b trial, which represent an important step forward in our efforts to bring new treatment options to patients living with this chronic condition.”
— Dr. Jane Doe, Chief Medical Officer, Enveda
What’s next
Enveda plans to move ENV-294 into a larger Phase 2 clinical trial later this year to further evaluate its safety and efficacy in a broader patient population.
The takeaway
The successful Phase 1b trial of Enveda's new drug candidate ENV-294 is a promising development that could eventually lead to a much-needed treatment option for those living with this chronic condition, pending the results of future clinical studies.
